Dermatologic adverse events associated with targeted therapies for melanoma.

Volume: 21, Issue: 3, Pages: 385 - 395
Published: Mar 1, 2022
Abstract
The development of new targeted therapies has considerably changed the therapeutic paradigm of melanoma, significantly increasing overall survival (OS) and progression-free survival (PFS). However, skin-related adverse sequelae might occur and impact on patients' quality of life.In this article we will cover the most important dermatological toxicities related to BRAF and MEK-inhibitors, along with updated management strategies.BRAF inhibitors...
Paper Details
Title
Dermatologic adverse events associated with targeted therapies for melanoma.
Published Date
Mar 1, 2022
Volume
21
Issue
3
Pages
385 - 395
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.